Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Interest Expenses (2020 - 2025)

Historic Interest Expenses for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to $725000.0.

  • Rani Therapeutics Holdings' Interest Expenses fell 4577.41% to $725000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 2948.3%. This contributed to the annual value of $5.0 million for FY2024, which is 102.26% down from last year.
  • According to the latest figures from Q3 2025, Rani Therapeutics Holdings' Interest Expenses is $725000.0, which was down 4577.41% from $877000.0 recorded in Q2 2025.
  • In the past 5 years, Rani Therapeutics Holdings' Interest Expenses registered a high of $1.3 million during Q3 2024, and its lowest value of -$1000.0 during Q4 2021.
  • For the 5-year period, Rani Therapeutics Holdings' Interest Expenses averaged around $835176.5, with its median value being $943000.0 (2025).
  • Per our database at Business Quant, Rani Therapeutics Holdings' Interest Expenses plummeted by 10172.41% in 2021 and then soared by 7200000.0% in 2022.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Interest Expenses stood at -$1000.0 in 2021, then surged by 72000.0% to $719000.0 in 2022, then skyrocketed by 80.25% to $1.3 million in 2023, then decreased by 13.27% to $1.1 million in 2024, then crashed by 35.5% to $725000.0 in 2025.
  • Its Interest Expenses was $725000.0 in Q3 2025, compared to $877000.0 in Q2 2025 and $943000.0 in Q1 2025.